International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- ——
- ——
The International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include multifocal mast cell infiltrates. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses systemic mastocytosis according to the International Consensus Classification (ICC) criteria using morphological, immunophenotypic, and molecular parameters. The ICC criteria refine the WHO classification system with enhanced diagnostic specificity for mast cell disorders.
Clinical Indication
The International Consensus Classification (ICC) Diagnostic Criteria for Systemic Mastocytosis is indicated for bedside clinical practice to support Diagnoses systemic mastocytosis according to the International Consensus Classification (ICC) criteria using morphological, immunophenotypic, and molecular parameters. The ICC criteria refine the WHO classification system with enhanced diagnostic specificity for mast cell disorders.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Exclude other potential genetic variants and secondary causes of elevated tryptase.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: High-sensitivity PCR recommended for KIT mutation detection with variant allele frequency (VAF) ≥1%.
Systemic Mastocytosis diagnosed if: Major Criterion present OR ≥3 Minor Criteria present
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| multifocal_mast_cell_infiltrates | string | Yes | Multifocal dense infiltrates of tryptase- and/or CD117-positive mast cells (≥15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s) - Major Criterion |
| atypical_mast_cell_morphology | string | Yes | In bone marrow/extracutaneous organs, >25% of mast cells are spindle-shaped or have atypical immature morphology - Minor Criterion 1 |
| aberrant_mast_cell_markers | string | Yes | Mast cells express additional markers CD25, CD2, or CD30 (in addition to standard mast cell markers) - Minor Criterion 2 |
| kit_mutation_detected | string | Yes | KIT D816V mutation or other activating KIT mutation detected in bone marrow, peripheral blood, or other extracutaneous organs using high-sensitivity PCR - Minor Criterion 3 |
| elevated_serum_tryptase | string | Yes | Elevated serum tryptase level persistently >20 ng/mL (not applicable in SM with associated myeloid neoplasm) - Minor Criterion 4 |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | — | ICC criteria met |
| — | — | ICC criteria not met |
Evidence-Based References (EBM)
- Leguit RJ, van der Linden MP, Jansen JH, Hebeda KM, Lam KH, Leenders WP, et al. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2023 Jan;482(1):99-112. doi: 10.1007/s00428-022-03454-6.DOI: 10.1007/s00428-022-03454-6
- Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.DOI: 10.1182/blood.2022015850
- Valent P, Akin C, Bonadonna P, Hartmann K, Alvarez-Twose I, Brockow K, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere. 2021 Oct 29;5(11):e646. doi: 10.1097/HS9.0000000000000646.DOI: 10.1097/HS9.0000000000000646